A recent report published by Infinium Global Research on lung
cancer therapeutics market provides an in-depth analysis of segments and
sub-segments in global as well as regional lung cancer therapeutics market. The
study also highlights the impact of drivers, restraints and macro indicators on
the global and regional lung cancer therapeutics market over the short term as
well as long term. The report is a comprehensive presentation of trends,
forecast and dollar values of global lung cancer therapeutics market. According
to report, the global lung cancer therapeutics market is projected to grow at a
CAGR of 12.50% over the forecast period of 2018-2024.
The report on global lung cancer therapeutics market covers
segments such as type of molecule and disease type. On the basis of the type of
molecule the global lung cancer therapeutics market is categorized into small
molecules and biologics. On the basis of disease type, the global lung cancer
therapeutics market is categorized into NSCLC and SCLC.
The report provides regional analysis covering geographies such as
North America, Europe, Asia-Pacific, and Rest of the World. In this section, the
key trends and market size for each geography are provided over the period of 2016-2024.
The countries covered in the North America region include the U.S., Canada, and
Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia,
and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe
are included in the European region. The U.S. drives the growth in the North
America region as it is the largest market in the region. The Asia-pacific region
offers a substantial potential for the market growth owing to rapid growth in
markets such as India and China. The
APAC region is projected to experience growth at a CAGR of x.x% over the
period of 2018-2024.
The report provides profiles of the companies in the global lung
cancer therapeutics market such as Astellas Pharma, Pfizer, Amgen, Celgene,
AstraZeneca, F. Hofmann-La Roche, GlaxoSmithKline, Aetna, Agennix, Eli Lilly
and Boston Biomedical.
The report provides deep insights on demand forecasts, market
trends, and micro and macro indicators. In addition, this report provides
insights into the factors that are driving and restraining the global lung cancer
therapeutics market. Moreover, IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of lung cancer therapeutics
market. Moreover, the study highlights current market trends and provides
forecast from 2018-2024. We also have highlighted future trends in the lung
cancer therapeutics market that will impact the demand during the forecast
period. Moreover, the competitive analysis given in each regional market brings
an insight into the market share of the leading players. This report will help
manufacturers, suppliers, and distributors of the lung cancer therapeutics
market to understand the present and future trends in this market and formulate
their strategies accordingly.